Oscar Health is a technology-first health insurer operating almost exclusively on the Affordable Care Act (ACA) individual exchange market. Founded in 2012 by Joshua Kushner, Mario Schlosser, and Kevin Nazemi, Oscar was built from the ground up as a cloud-native insurer designed to make the consumer health insurance experience feel like a modern digital product rather than a legacy bureaucratic nightmare. It went public in February 2021 at $39/share, implying a valuation nearly twice its current enterprise value.

What it sells and to whom. Oscar sells individual and family health insurance plans through the federal ACA marketplace (Healthcare.gov) and state-based exchanges, primarily to individuals who are self-employed, between jobs, or ineligible for employer-sponsored coverage. Plans are offered across the standard metal tiers — Bronze, Silver, Gold, and Platinum — with Bronze-heavy enrollment consistent with the younger, cost-sensitive profile Oscar tends to attract. Oscar operates in approximately 20 states, with its most material footprint in Florida, Texas, Georgia, and California.

Revenue architecture. Revenue is overwhelmingly premium-based — roughly 97–98% of total revenue represents premium income from members plus federal Advanced Premium Tax Credits (APTCs) paid directly to the insurer. Investment income on the float and a de minimis services/platform revenue line (the "+Oscar" B2B business) make up the balance. There is no material employer-group, Medicaid, or Medicare Advantage book — Oscar is a pure-play ACA exchange insurer, which is simultaneously its greatest growth engine and its most concentrated risk.

Revenue quality. ACA premiums are locked in for 12-month plan periods, providing reasonable near-term predictability within a given plan year. However, this is not a subscription business in the traditional sense — members re-enroll annually during Open Enrollment (November–January), and retention rates are meaningfully below true SaaS-style businesses. The company does not disclose retention explicitly, but industry churn on ACA plans runs 20–30% annually, meaning Oscar must re-win a significant fraction of its book each year.

Unit economics. At approximately $18.85B in 2026 revenue against ~3.4M members, revenue per member per year runs roughly $5,500, growing due to pricing actions. Customer acquisition occurs primarily through ACA exchange listing, brokers, and direct digital marketing. Medical loss ratio (MLR) — the percentage of premiums spent on actual medical claims — is the dominant swing factor in profitability. Oscar's full-year 2026 MLR guidance of 82.4–83.4% implies roughly $0.17 on the dollar reaches the company before SG&A. With SG&A guided at 15.8–16.3% of revenue, operating margins are thin but finally moving into positive territory.

Pricing power. Oscar implemented aggressive rate increases of approximately 28% for the 2026 plan year — a pricing action that simultaneously re-priced the book after 2025's elevated morbidity and partially offset the expiration of enhanced ACA subsidies. The fact that Oscar added members despite these increases suggests the brand and product quality create genuine consumer preference, though the broader market contracted from 24.3M to 22.8M enrollees nationally. Oscar's ability to grow share in a shrinking market is a meaningful positive signal.

Geographic and customer concentration. Oscar is concentrated in the individual ACA market by design. No single customer exceeds 10% of revenue, but regulatory dependency on the federal government (for APTC payments and risk-adjustment transfers) represents a quasi-customer concentration that investors should not overlook. Florida, Texas, and Georgia likely represent the majority of Oscar's membership.

Revenue history. Oscar has grown at a remarkable clip: from roughly $400M in 2020 to $3.3B in 2023, $9.2B in 2024, $11.7B in 2025, and a guided $18.85B in 2026. Much of this growth is driven by ACA enrollment expansion (fueled by enhanced subsidies from 2021–2025) and Oscar taking disproportionate market share through pricing and consumer experience.

Profitability trajectory. Oscar has spent most of its existence burning cash. From 2021 through 2024, net losses accumulated heavily as the company over-expanded into markets where its MLR exceeded 100% — meaning it paid more in claims than it collected in premiums. The 2025 loss of $443M was driven by market-wide morbidity surprises (sicker-than-expected members), particularly in the back half of the year when Q4 MLR spiked to 95.1%. The company's MLR history shows meaningful volatility, which is the fundamental risk of this business.

Cash flow quality. Oscar generated $2.618 billion of net cash from operations in Q1 2026 alone — an extraordinary figure driven by the timing of premium collections ahead of claims payments. Insurance businesses naturally generate cash before paying claims, but this is partially offset by regulatory requirements to hold risk-based capital. The true quality of earnings will be judged over a full claim cycle, not a single quarter where utilization was below seasonal norms.

Balance sheet. As of early 2026, Oscar held approximately $2.77B in cash and investments with a new $475M revolving credit facility (secured February 2026, three-year term). The company exchanged a portion of its 2031 convertible notes in late 2025. Debt-to-equity runs approximately 0.51x at recent stock prices. Crucially, Oscar relies on reinsurance partners covering approximately 55% of required capital, which limits equity dilution but introduces third-party dependency. Net cash position is positive, and there is no near-term liquidity crisis.

Capital intensity and working capital. Oscar is not capital-intensive in the traditional sense — it does not own hospitals or clinics. Its capital consumption is regulatory (state-mandated risk-based capital minimums) and technology-related (product development, platform investment). Working capital dynamics are favorable: premiums and APTC flows arrive monthly, claims are paid with a lag. The business structurally generates pre-claims cash, which is why Q1 operating cash flow looks extraordinary.

ROIC. Trailing ROIC remains deeply negative at approximately -24%, reflecting years of cumulative losses. The company is just now emerging from that hole. A fair read on forward ROIC requires 2–3 years of sustained profitability to assess, but the trajectory is clearly improving. The business model, if it achieves and maintains an MLR in the low 80s with continued SG&A leverage, can structurally earn 10–15%+ ROIC at scale — comparable to mature managed care companies.

Mark Bertolini — Chief Executive Officer. Bertolini joined Oscar in April 2023, replacing co-founder Mario Schlosser. He is 69 years old and brings a heavyweight managed care résumé: he served as CEO of Aetna from November 2010 to November 2018, growing it from a mid-tier insurer into one of the nation's largest before its $69B acquisition by CVS Health. Prior to Aetna, he held senior roles at Cigna, NYLCare, and SelectCare — making him one of the most operationally experienced health insurance executives in America. He also served as Co-CEO of Bridgewater Associates (2019–2023), which gave him financial markets exposure.

Track record at Oscar. Bertolini arrived during a period of elevated losses. His 2026 strategy — aggressive repricing, operational discipline, AI-driven cost reduction, and selective market footprint — appears to be working. Q1 2026's record profitability is the most direct validation of his tenure. The SG&A ratio has declined from 25%+ in 2023 to 15.2% in Q1 2026, a remarkable improvement driven by headcount discipline and technology investment. However, fair attribution requires noting that some 2025 performance setbacks (the morbidity spike) were partly macro-driven rather than management-driven.

Governance structure. Oscar operates with a dual-class share structure — Class A (public) and Class B/C shares held by founders. Joshua Kushner (Thrive Capital) serves as Vice Chairman; co-founder Mario Schlosser remains involved. Bertolini is Chairman and CEO, which concentrates power and is a governance negative in theory, though his operational track record at Aetna partially offsets the concern. The board includes a mix of healthcare veterans and technology-focused directors. Independent oversight is present but constrained by founder influence through super-voting shares.

Key lieutenants. The CFO is Scott Blackley, who has provided consistent and credible financial guidance through the company's operational reset. The management team has been largely stable through the Bertolini era, and the Q1 2026 call reflected a team that has internalized operational metrics (MLR by cohort, SG&A ratio drivers, reinsurance structure) at a sophisticated level. The absence of visible C-suite turnover during the difficult 2025 period is a positive signal.

Compensation. Bertolini's inducement equity package (granted April 2023) includes time-based RSUs vesting in three annual tranches plus PSUs with stock price hurdles at $11, $16, and $39. The $11 and $16 hurdles were achieved in 2024; the $39 hurdle remains. This aligns CEO compensation with long-term stock price appreciation, not just short-term MLR beats. His $12M personal capital commitment at $11.92 is a stronger alignment signal than any compensation structure, however.

Does a moat exist? The honest answer is: a narrow one, and one that is more durable in its data/technology dimension than in its brand or pricing dimension. Oscar is not a capital-light software company masquerading as an insurer — it bears full insurance risk and competes with massive, well-capitalized incumbents. But it has built real structural advantages that are worth analyzing carefully.

Technology platform as moat. Oscar's cloud-native technology stack — built from scratch rather than assembled from legacy acquisitions — gives it meaningfully lower unit costs to administer a health plan than traditional insurers. The company's ability to bring SG&A down from 30%+ to 15% while scaling membership more than 10x is empirical evidence that the technology advantage is real. The +Oscar platform (sold to other health systems and payors as a B2B SaaS tool) represents a nascent second moat, though it remains a rounding error on revenue today.

Data as moat. Three million+ members on an integrated digital platform generates proprietary claims and utilization data at a granularity traditional insurers cannot match. This data informs pricing, risk selection, and care management in ways that compound over time. Oscar's AI-driven predictive analytics for claims management is a genuine differentiator that incumbents with fragmented legacy systems struggle to replicate quickly.

Brand and consumer experience. Oscar's NPS and member experience metrics are reportedly above industry averages. In a market where health insurance is universally despised, building brand loyalty is a genuine competitive advantage. The "Buena Salud" Spanish-first product and ICHRA (Individual Coverage Health Reimbursement Arrangement) capabilities serve underserved segments that larger incumbents have been slower to address.

Moat trend. The moat appears to be widening, but slowly. The SG&A leverage trajectory, improving MLR trend (excl. 2025 morbidity surprise), and growing +Oscar platform suggest the technology advantage is compounding. The exit of CVS Health from the ACA exchange market in 2026 is a tailwind that competitors with weaker technology than Oscar cannot exploit as effectively — Oscar can absorb displaced members at marginal cost far more efficiently than incumbents running legacy systems.

TAM and secular tailwinds. The individual ACA exchange market was roughly 24.3M enrollees at its 2025 peak, the largest in its history, driven by enhanced subsidies from the American Rescue Plan and Inflation Reduction Act. The U.S. individual and small-group health insurance market represents hundreds of billions in annual premium. Secular tailwinds include rising gig economy participation (self-employed workers without employer coverage), workforce volatility, and ongoing erosion of employer-sponsored coverage among small businesses — all structural forces that expand the addressable market for exchange-based insurers.

Subsidy expiration — the dominant near-term headwind. The enhanced APTCs (which reduced or eliminated premiums for households up to 400% of the federal poverty line) expired at the end of 2025. This resulted in national ACA enrollment falling from 24.3M to approximately 22.8M — a decline of roughly 6%, less catastrophic than some feared but still directionally negative. For lower-income members who were subsidy-dependent, effective net premiums rose sharply. Oscar's 28% rate increase for 2026 was designed to partially offset this market shrinkage with higher revenue per member, and the Q1 2026 results suggest this strategy is working.

Competitive landscape. The ACA exchange market has consolidated significantly. Bright Health failed; Clover Health remains subscale; CVS Health exited. The surviving major players are UnitedHealth (through its exchange offerings), Centene (Ambetter — the largest ACA insurer), Elevance, Blue Cross Blue Shield affiliates, Molina Healthcare, and Oscar. Oscar is the only pure-play, technology-native insurer of scale. Centene competes most directly as a volume player in the lower-income segment, but Oscar increasingly differentiates on experience rather than pure price.

Regulatory environment. The ACA regulatory environment is a two-sided sword. On the protective side, the ACA's guaranteed issue, community rating, and risk-adjustment transfer system (which distributes money from plans with healthier-than-average members to plans with sicker members) prevents Oscar from being catastrophically disadvantaged by adverse selection in a given year. On the threatening side, every congressional session brings the possibility of subsidy changes, enrollment rule modifications, and risk-adjustment methodology shifts. The proposed shortening of open enrollment to December 15 and elimination of Special Enrollment Periods for lower-income households are regulatory headwinds that management is actively lobbying against.

Cyclicality. ACA exchange insurers are more sensitive to regulatory changes than traditional economic cycles. Oscar did not exist in 2008–2009. During the 2020 COVID downturn, ACA enrollment actually increased as job losses pushed people from employer coverage to exchanges — suggesting the business has some counter-cyclical characteristics.

Why the EV/Revenue multiple is deceptive. At 0.25x EV/Revenue, OSCR screens as absurdly cheap versus UnitedHealth at 0.80x. But this comparison is misleading: Oscar is not a diversified managed care company — it is a pure-play ACA insurer with concentrated regulatory risk, an unproven multi-year profitability track record, and no Medicare Advantage, Medicaid, or commercial group business to provide earnings diversification. A discount to UNH is justified; the question is how large the discount should be.

DCF sanity check. Using conservative 2026 Adj. EBITDA of $400M (midpoint of guidance plus $115M adjustment), growing at 15% annually through 2030, then 5% in perpetuity, discounted at 11%: intrinsic value comes to approximately $18–22/share. This suggests the stock at $21 is trading near fair value on the base case — not deeply undervalued, not egregiously overvalued. The upside in the bull case (faster-than-expected margin expansion, +Oscar monetization, continued market share gains) pushes the DCF to $28–35.

Why the stock is at its current price. OSCR was as low as $10.69 in the past 52 weeks, reflecting deep investor skepticism about: (1) the ACA subsidy expiration causing a massive enrollment collapse, (2) the 2025 MLR spike indicating fundamental underwriting flaws, and (3) management's credibility after repeated guidance misses in 2025. The stock has surged 47% in 30 days and 65% in 90 days on a combination of: Q1 2026 blowout earnings (EPS of $2.07 vs $1.12 estimate), guidance reaffirmation, and the ACA enrollment decline proving less catastrophic than feared.

Value trap risk assessment. Oscar is not a value trap in the classic sense — the business model is not in structural decline. The risk is that at $21, the stock has already re-rated significantly for a profitability story that has only one quarter of evidence. Full-year 2026 EPS of $0.77 implies a 27x P/E — expensive for an insurer, even a high-growth one — and that assumes H2 executes flawlessly.

Dividends. None. Oscar does not pay a dividend and will not in the foreseeable future. As a company still generating its first material profits, capital retention is appropriate.

Share buybacks. Share count has decreased by 1.3% in the past year — modest and primarily reflecting the partial retirement of convertible notes and no material new equity issuance. There is no systematic buyback program. SBC dilution is non-trivial given the large inducement equity package granted to Bertolini in 2023 (RSUs and PSUs through 2026).

M&A track record. Oscar has not made material acquisitions. Its +Oscar B2B platform was built internally. This is appropriate for a company that was burning cash through 2025 — capital discipline has been the right call. Going forward, as the balance sheet strengthens, the risk of value-destructive empire-building exists but is not evident in management's current signaling.

Organic reinvestment. The primary capital allocation priority is investing in technology (AI, care management platform, member engagement tools) and expanding geographic footprint selectively. The payoff is visible in SG&A leverage (300 bps improvement over two years) and improving MLR through better risk selection.

Reinsurance capital strategy. Oscar's decision to partner with reinsurers to cover 55% of required risk capital is an intelligent form of capital allocation — it allows growth without commensurate equity dilution, at the cost of ceding some underwriting profit. This arrangement is common in the industry and reflects sophisticated balance sheet management.

Stated strategic priorities. Bertolini's 2026 agenda has three pillars: (1) complete the transition to sustainable profitability by holding MLR below 83.4% while scaling revenue 61%; (2) accelerate the +Oscar B2B platform to diversify revenue beyond ACA premiums; (3) invest in AI-driven operational efficiency to drive SG&A below 16% of revenue.

Early evidence of progress. Q1 2026 provides the most compelling evidence to date. The 70.5% MLR is extraordinary (even adjusting for favorable seasonal factors), the $679M net income is the highest in company history, and the SG&A ratio improved 60 bps year-over-year. The company also grew membership 56% in a market that contracted overall — demonstrating pricing power and brand appeal simultaneously. Guidance was reaffirmed in full after the strongest quarter in company history, suggesting management is not sandbagging the full year.

Pricing discipline. The 28% rate increase for 2026 was a high-risk, high-reward move. It risked member attrition but secured a book that is expected to be more profitable per unit. The early evidence — membership at 3.2M with above-expectation retention — suggests the pricing decision was correct.

Management credibility on guidance. This is a nuanced point. In 2025, management revised guidance downward multiple times as morbidity exceeded expectations, which damaged credibility. In 2026, Q1 results have come in dramatically above expectations, and guidance has been reaffirmed — but this is the first quarter. The critical test will be whether Q2–Q4 holds within the 82.4–83.4% MLR band. Management has earned a yellow flag, not a green or red one.

Potential near-term catalysts (12–24 months).

AI as operational tool — quantified impact. Oscar explicitly credits AI and technology investments with its SG&A improvement — the Q1 2026 earnings transcript specifically cited "growing impact of AI across our operations and member services" as a driver of the 60 bps SG&A improvement. This is not marketing language; the SG&A ratio has compressed from 25%+ in 2023 to 15.2% in Q1 2026 despite massive revenue growth, which can only be achieved with genuine technology-driven efficiency. AI applications include: predictive claims triage, automated prior authorization processing, intelligent member routing in care navigation, and claims runout modeling.

AI as revenue opportunity — +Oscar platform. The +Oscar platform represents Oscar's attempt to monetize its technology stack by licensing it to other health systems and payors. The Campaign Builder (an engagement and recommendation platform for providers and payors) and the enrollment/brokerage tools are the core products. Revenue from +Oscar remains de minimis today (services revenue is <2% of total), but the platform could become meaningful over a 3–5 year horizon if large payors adopt it. This would fundamentally change Oscar's business model from pure risk-bearing insurer to tech-enabled managed care services company — a significantly higher multiple business.

AI as competitive defense. The primary AI threat to Oscar is not disruption of its product but acceleration of incumbent competition. UnitedHealth's Optum division, Centene's internal technology investments, and Elevance's health services expansion all represent AI-powered competitive moves. Oscar's 7-year head start on cloud-native architecture is a real advantage, but incumbents with 10x the R&D budget can close gaps faster than in prior technology cycles.

Data assets. Oscar's integrated member platform generates longitudinal health data (claims, care navigation interactions, app engagement, telehealth encounters) for 3.2M+ members. This is proprietary data with real AI training value — both for improving Oscar's own models and potentially (with appropriate privacy frameworks) for licensing to pharmaceutical or health analytics companies. The monetization of this data asset is underappreciated by the market.

R&D posture. Oscar does not break out R&D as a separate line, but the SG&A efficiency trajectory strongly implies that technology investment is generating returns. The company positions itself as "a leading healthcare technology company" — a framing that aspires to the valuation multiples of technology businesses rather than insurance companies. Whether the market eventually grants that multiple is the key valuation swing factor.

Insider ownership. CEO Mark Bertolini holds approximately 10.87% of the company (~10.2M shares, worth ~$215M at current prices). Co-founder Joshua Kushner and Thrive Capital hold a substantial stake through multiple share classes. The 12-month insider transaction history shows 17 sells and only 1 buy (Bertolini's $12M purchase at $11.92 in April 2026). The sells likely represent tax-related disposals of vested RSUs rather than outright bearish conviction, but the net insider activity is not a bullish signal at the aggregate level — only Bertolini's direct open-market purchase is.

Institutional holders. Major institutional shareholders include Vanguard, BlackRock, and various healthcare-focused funds. Institutional ownership has increased as the stock attracted attention from managed care specialists. The 65% stock gain over the past 90 days suggests institutional buyers (not just retail) have been accumulating — short-covering on Q1 beat likely contributed to the sharp post-earnings move.

Short interest analysis. At 8.91% of float, short interest is elevated and reflects genuine skepticism about Oscar's ability to sustain profitability through the full year. Short sellers will focus on H2 MLR as their primary thesis. If Q2 and Q3 MLR comes in within guidance, the remaining short sellers will face a squeeze. If MLR spikes unexpectedly, shorts will be validated and the stock will retrace sharply.

Analyst landscape. Of 10 analysts: Goldman Sachs (Hold), UBS (Neutral, target $20), Barclays (raised target to $21), Baird (raised to $19), Wells Fargo (Sell), Jefferies (Underperform, target $12). The spread from $11 to $30 is enormous, reflecting genuine analytical disagreement about the company's trajectory. Post-Q1, consensus has shifted meaningfully toward the bull case — but there remain sophisticated Sell-rated analysts who believe the H2 risk is underpriced.

Activist involvement. No known activist involvement. The dual-class share structure makes hostile activism extremely difficult regardless.

Asymmetry assessment. At $21, the upside/downside ratio is approximately 1.5:1 — meaningful but below the 2:1 threshold that characterizes a compelling asymmetric investment. The stock already reflects a substantial portion of the good news from Q1. A pullback toward $15–$17 (where the stock was trading before the Q1 beat) would improve the asymmetry to approximately 3:1, making the risk/reward genuinely compelling.